Overview

Safety of CHIR-258 (TKI258) in Advanced Solid Tumors

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I dose finding study in solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Collaborator:
Chiron Corporation